Army medical research and development sbir phase III contract titled advancement of advancement broad-spectrum snakebite antidote.
Ended Definitive Contract Awarded Last action
- Contract number
- W81XWH20C0017
- Awardee
-
Ophirex, Inc. UEI W452WY5E2JQ9
- Awarding agency
-
Medical Command
Department of the Army, Department of Defense
- Obligated
- $4,576,082
Award facts
- Opportunity
-
- 75N91018R1PHS Solicitation number
- Contract value 49% obligated
- $9,407,618.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Corte Madera, CA 94925, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Funding Only Action | $131,169 | |
| Exercise an Option | $206,140 | |
| Supplemental Agreement for work within scope | $1,581,649 | |
| Funding Only Action | $957,582 | |
| Supplemental Agreement for work within scope | $657,000 | |
| Supplemental Agreement for work within scope | $2,255,578 | |
| Original award | $3,618,500 |
About this award
The U.S. Army Medical Research and Development Command awarded a Small Business Innovation Research (SBIR) Phase III definitive contract to Ophirex, Inc., a small business located in Corte Madera, California, for the advancement of a broad-spectrum snakebite antidote. The contract, valued at $9.4 million with a completion date of November 30, 2023, supports the development of varespladib, a phospholipase A2 inhibitor designed to inhibit snake venom toxins and provide more effective treatment for snakebite victims. The firm fixed price contract was awarded on June 1, 2020, with Modification P00003 providing incremental funding for continued development efforts.
Ophirex's research focuses on developing both oral and intravenous formulations of varespladib to address the limitations of current antivenom treatments by targeting secretory phospholipase A2, which is present in approximately 95 percent of medically important venomous snakes. The contract work is performed in Corte Madera, California, as part of the Army's broader initiative to advance medical countermeasures for snakebite envenomation. This SBIR Phase III award reflects the Department of Defense's commitment to innovative pharmaceutical solutions that can reduce death and disability from snakebite through advanced medical interventions developed by small businesses.
Quick answers
Who was awarded contract W81XWH20C0017?
W81XWH20C0017 was awarded to Ophirex, Inc. by Medical Command (Department of the Army) on June 1, 2020.
How much is contract W81XWH20C0017 worth?
The government has obligated $4,576,082 on W81XWH20C0017. Its current value, with exercised options, is $9,407,618.
Was contract W81XWH20C0017 competed?
The government received 1 offer. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award